PTC Therapeutics (PTCT) News Today

Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Get Free Report) have earned a consensus rating of "Hold" from the sixteen analysts that are currently covering the firm, Marketbeat.com reports. Three research analysts have rated the stock with a sell recommendation, six have given a hold recommenda

Renaissance Technologies LLC boosted its stake in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 7.4% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 818,100 shares of the biopharmaceutical company's stock after

Cantor Fitzgerald reiterated an "overweight" rating and set a $64.00 price objective on shares of PTC Therapeutics in a research note on Tuesday.

PTC Therapeutics (NASDAQ:PTCT) Stock Price Up 5.7%

Bank of New York Mellon Corp raised its stake in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 17.1% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 279,049 shares of the biopharmaceutical company's stock after purchasing an additional 40,840 shares duri

Cowen AND Company LLC grew its position in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 0.8% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 3,756,469 shares of the biopharmaceutical company's stock

PTC Therapeutics (NASDAQ:PTCT) Trading Down 4.6%

Baird R W upgraded shares of PTC Therapeutics to a "strong-buy" rating in a report on Wednesday.

Robert W. Baird began coverage on shares of PTC Therapeutics in a research note on Wednesday. They set an "outperform" rating and a $44.00 price objective on the stock.

Panagora Asset Management Inc. increased its stake in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 9.1% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 315,100 shares of the biopharmaceutical company's stock after purch

PTC Therapeutics (NASDAQ:PTCT) Shares Gap Up to $34.15

UBS Group initiated coverage on PTC Therapeutics in a research note on Monday. They issued a "buy" rating and a $47.00 price target on the stock.

Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Get Free Report) have been assigned a consensus recommendation of "Hold" from the thirteen brokerages that are currently covering the company, Marketbeat reports. Three equities research analysts have rated the stock with a sell recommendation, six ha

Neo Ivy Capital Management bought a new stake in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 40,708 shares of the biopharmaceutical company's stock, valued at a

Assenagon Asset Management S.A. increased its stake in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 21.7% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 372,827 shares of the biopharmaceutical company's stock after

PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) - Equities research analysts at William Blair issued their FY2026 earnings per share (EPS) estimates for shares of PTC Therapeutics in a research note issued to investors on Friday, August 9th. William Blair analyst S. Corwin expects that the bio

Cantor Fitzgerald boosted their price target on PTC Therapeutics from $62.00 to $64.00 and gave the company an "overweight" rating in a research report on Friday.

PTC Therapeutics (NASDAQ:PTCT) Shares Gap Down After Earnings Miss

Burney Co. bought a new position in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 42,040 shares of the biopharmaceutical company's stock, valued at approximately $1,223,000. Burney C

Price T Rowe Associates Inc. MD cut its stake in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 35.9% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 639,867 shares of the biopharmaceut

PTC Therapeutics (NASDAQ:PTCT) will be releasing earnings after the market closes on Thursday, August 8, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=613390)

Janus Henderson Group PLC lifted its stake in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 40.5% in the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 3,669,816 shares of the biopharmaceutical company's stock after purchasing an additiona

Healthcare of Ontario Pension Plan Trust Fund acquired a new position in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) in the first quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 113,500 shares of the biopharmaceutical company's stock, valued at

Seven Eight Capital LP grew its holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 148.3% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 58,692 shares of the biopharmaceutical company's stock after p

Edgestream Partners L.P. boosted its position in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 49.3% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 53,522 shares of the biopharmaceutical company's

Russell Investments Group Ltd. increased its position in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 57.9% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 301,790 shares of th

BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its stake in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 8.7% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 439,365 shares of t

Empowered Funds LLC bought a new position in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 41,598 shares of the biopharmaceutic